Literature DB >> 30233733

Protective role of fentanyl in lipopolysaccharide-induced neuroinflammation in BV-2 cells.

Jian Wang1, Yingjie Jin2, Jianchun Li2.   

Abstract

Neurosurgery always results in neuroinflammation, which may activate microglial cells. Previous studies have demonstrated that fentanyl could be used for the induction or maintenance of anesthesia prior to surgery. However, it is unknown if fentanyl attenuates neuroinflammation prophylactically. Cell viability in groups that were treated with different concentrations of fentanyl (0.01, 0.1, 1 or 5 µmol/l) was analyzed by an MTT assay. BV-2 microglial cells were treated with lipopolysaccharide (LPS) at a concentration of 1 µg/ml to mimic neuroinflammation in vitro. BV-2 cells were pretreated with 5 µmol/l fentanyl prior to stimulation by LPS. The protein levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in the culture medium were assessed by ELISA. The mRNA level of toll-like receptor (TLR)4 was evaluated by reverse transcription-quantitative polymerase chain reaction analysis. The protein levels of TLR4, glycogen synthase kinase (GSK)-3β and phosphorylated (p)-GSK-3β in BV-2 cells were assessed by western blot analysis. The MTT assay demonstrated that low concentrations of fentanyl (0.01, 0.1 or 1 µmol/l) did not affect the cell viability of BV-2 cells, while 5 µmol/l fentanyl significantly reduced BV-2 cell viability. The results of ELISA revealed that LPS significantly upregulated the release of TNF-α, IL-1β and IL-10, which were repressed by fentanyl pretreatment. Fentanyl pretreatment significantly reduced the LPS-induced elevation of TLR4 at mRNA and protein levels as well as p-GSK-3β protein levels in BV-2 cells. In conclusion, fentanyl pretreatment protects BV-2 cells from LPS-induced neuroinflammation by inhibiting TLR4 expression and GSK-3β activation. Neuroinflammation induced by surgery serves an important role in the development of postoperative cognitive dysfunction (POCD) and targeting the TLR4 and GSK-3β signaling pathway may provide a novel therapeutic approach for the treatment of POCD.

Entities:  

Keywords:  BV-2 cells; fentanyl; glycogen synthase kinase-3β; neuroinflammation; toll-like receptor 4

Year:  2018        PMID: 30233733      PMCID: PMC6143851          DOI: 10.3892/etm.2018.6590

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  34 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.

Authors:  Liya Qin; Xuefei Wu; Michelle L Block; Yuxin Liu; George R Breese; Jau-Shyong Hong; Darin J Knapp; Fulton T Crews
Journal:  Glia       Date:  2007-04-01       Impact factor: 7.452

3.  Toll-like receptor-4 knockout mice are more resistant to optic nerve crush damage than wild-type mice.

Authors:  Dana Morzaev; James D Nicholson; Tomm Caspi; Shirel Weiss; Edith Hochhauser; Nitza Goldenberg-Cohen
Journal:  Clin Exp Ophthalmol       Date:  2015-05-13       Impact factor: 4.207

4.  Walnut extract inhibits LPS-induced activation of BV-2 microglia via internalization of TLR4: possible involvement of phospholipase D2.

Authors:  Lauren M Willis; Donna F Bielinski; Derek R Fisher; Nirupa R Matthan; James A Joseph
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

5.  Bone marrow-derived mesenchymal stem cells modulate BV2 microglia responses to lipopolysaccharide.

Authors:  Yin Yin Ooi; Rajesh Ramasamy; Zul'atfi Rahmat; Hemavathy Subramaiam; Shi Wei Tan; Maha Abdullah; Daud Ahmad Israf; Sharmili Vidyadaran
Journal:  Int Immunopharmacol       Date:  2010-09-16       Impact factor: 4.932

6.  The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS.

Authors:  Seija Lehnardt; Christian Lachance; Silvia Patrizi; Sharon Lefebvre; Pamela L Follett; Frances E Jensen; Paul A Rosenberg; Joseph J Volpe; Timothy Vartanian
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 7.  Transdermal fentanyl: pharmacology and toxicology.

Authors:  Lewis Nelson; Robert Schwaner
Journal:  J Med Toxicol       Date:  2009-12

Review 8.  The potential for mu-opioid receptor agonists to be anti-emetic in humans: a review of clinical data.

Authors:  Kevin D Johnston
Journal:  Acta Anaesthesiol Scand       Date:  2009-10-10       Impact factor: 2.105

9.  Neuroprotective effects of pretreatment with propofol in LPS-induced BV-2 microglia cells: role of TLR4 and GSK-3β.

Authors:  Bo Gui; Mingyan Su; Jie Chen; Lai Jin; Rong Wan; Yanning Qian
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

Review 10.  The role of inflammation in CNS injury and disease.

Authors:  Sian-Marie Lucas; Nancy J Rothwell; Rosemary M Gibson
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

View more
  5 in total

Review 1.  Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse.

Authors:  Ying Han; Lu Cao; Kai Yuan; Jie Shi; Wei Yan; Lin Lu
Journal:  Neurosci Bull       Date:  2022-05-15       Impact factor: 5.271

2.  Involvement of Anti-Inflammatory and Stress Oxidative Markers in the Antidepressant-like Activity of Aloysia citriodora and Verbascoside on Mice with Bacterial Lipopolysaccharide- (LPS-) Induced Depression.

Authors:  Denise B Gomes; Patrícia Z Serpa; Daniela Miorando; Maria Eduarda D C Zanatta; Camila S Carteri; Lincon B Somensi; Larissa Venzon; Ana C Santos; Tauani C S França; Luísa M Silva; Walter A Roman Junior
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-22       Impact factor: 2.650

3.  Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances.

Authors:  Valeria Sogos; Paola Caria; Clara Porcedda; Rafaela Mostallino; Franca Piras; Cristina Miliano; Maria Antonietta De Luca; M Paola Castelli
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

4.  Forsythoside B attenuates memory impairment and neuroinflammation via inhibition on NF-κB signaling in Alzheimer's disease.

Authors:  Fan'ge Kong; Xue Jiang; Ruochen Wang; Siyu Zhai; Yizhi Zhang; Di Wang
Journal:  J Neuroinflammation       Date:  2020-10-15       Impact factor: 8.322

5.  Chrysomycin A Attenuates Neuroinflammation by Down-Regulating NLRP3/Cleaved Caspase-1 Signaling Pathway in LPS-Stimulated Mice and BV2 Cells.

Authors:  Man Liu; Shan-Shan Zhang; Dong-Ni Liu; Ying-Lin Yang; Yue-Hua Wang; Guan-Hua Du
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.